# LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

> **NCT02964247** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 303 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** liraglutide
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02964247
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-03
- **Primary completion:** 2018-05-04
- **Final completion:** 2018-05-08
- **Target enrollment:** 303 (ACTUAL)
- **Last updated:** 2020-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02964247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02964247, "LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02964247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*